Heart Failure

Statins have been found to moderately benefit patients with cardiovascular disease risk factors, but researchers found socioeconomic disparities among those treated with statins.

Researchers find that the risk of developing dementia increased by 35% in patients with atrial cardiopathy.

Early detection of chronic kidney disease is vital to preventing comorbid conditions.

Results also show that no association with an increased frequency of myocarditis, venous thromboembolism, or worsening HF in these individuals.

Treatment with empagliflozin also found to improve cardiac geometry, myocardial mechano-energetic efficiency, and cardiac function.

Insurer and pharmacy benefit manager policies used to cut the cost of drugs could be so time consuming that they could put newly diagnosed atrial fibrillation patients at risk of stroke.

Analysis supports positive lifestyle habits, such as exercising and quitting smoking, investigators say.

Globally, more than 40 million patients are currently taking an ACE inhibitor, primarily for the treatment of high blood pressure and heart failure.

Study finds that only 19.6% of US adults have high cardiovascular health, whereas 62.5% have moderate health and 17.9% have low.

Compared to atorvastatin, rosuvastatin was associated with higher risks of blood in the urine and kidney failure that requires replacement therapy.

Records from 11 million patients shows that non-alcoholic fatty liver disease could increase the risk of developing heart failure by 50%.

Empagliflozin also was associated with Improvement in quality of life and greater reduction in body weight.

Results are first to show causal relationship between losing mLOY in the blood and development of cardiovascular disease.

Patients with heart failure in bereavement are at a higher risk of death from the condition, particularly in the first week following a family member’s death.

Sacubitril and Valsartan (Entresto) is indicated to reduce the risk of cardiovascular death and hospitalization in adult patients with chronic heart failure.

Pravastatin sodium (Pravachol) is indicated as an adjunctive therapy to diet to lower the risk of myocardial infarction, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident congenital heart disease.

Many patients with heart failure are hesitant to receive the COVID-19 vaccine due to the fear of myocarditis.

The researchers noted that new therapies have faced challenges because of this knowledge gap in CHD.

Jardiance shows reduction of 50% compared with dipeptidyl peptidase-4 inhibitors and 30% compared with glucagon-like peptide 1 receptor agonists.

Tolvaptan (Jynarque )is a selective vasopressin V2-receptor antagonist .

The gout medicine is a potential treatment option for individuals hospitalized for the cardiovascular condition, analysis suggests.

Sacubitril/valsartan (Entresto)reduces the risk of hospitalization and death related to cardiovascular complications in patients with heart failure.

Scientific abstracts also address findings on cardiovascular disease and population, the connection between COVID-19 and HF, and links between prognosis and marital status.

Medications are the primary cause of acquired QT-prolongation, although the exact mechanism of why some people evoke torsades de pointes but others do not is still unknown.

Metformin has been the drug of choice for the treatment of diabetes since the 1950s, but new changes suggest the consideration of SGLT-2 inhibitors or GLT-1 agonists.

Results from the DELIVER and DAPA-HF phase 3 trials demonstrate AstraZeneca’s Farxiga’s efficacy in heart failure, regardless of ejection fraction.

How would you handle these patients' questions?

Patients taking the product should consult with their physician or pharmacist to determine whether they have the affected product.

Among Black and Latina women with heart failure, negative health outcomes are magnified due to significant health disparities and inequities in the management of the chronic condition.

Empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) tablets are the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death.